Gilead Sciences (NASDAQ:GILD) Now Covered by Truist Financial

Truist Financial initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $140.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on GILD. Wells Fargo & Company increased their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Finally, TD Cowen increased their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $130.65.

Gilead Sciences Stock Performance

Shares of GILD opened at $125.27 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm’s fifty day simple moving average is $118.73 and its two-hundred day simple moving average is $113.94. Gilead Sciences has a 12 month low of $88.57 and a 12 month high of $128.70. The stock has a market capitalization of $155.42 billion, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the previous year, the business earned $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts predict that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the sale, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 125,146 shares of company stock worth $15,148,441. Company insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. One Wealth Advisors LLC raised its position in shares of Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares in the last quarter. Ariel Investments LLC increased its stake in Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after acquiring an additional 30,630 shares during the last quarter. Sivik Global Healthcare LLC boosted its position in shares of Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after acquiring an additional 10,000 shares during the last quarter. Simplify Asset Management Inc. boosted its position in shares of Gilead Sciences by 148.6% during the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Finally, VeraBank N.A. purchased a new position in shares of Gilead Sciences during the second quarter worth about $397,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.